Hope Rugo

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    H S Rugo
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, USA
    Ann Oncol 25:808-15. 2014
  2. pmc Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
    Hope S Rugo
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1710, San Francisco, CA, 94143 1710, USA
    Breast Cancer Res Treat 141:461-70. 2013
  3. pmc Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
    A Jo Chien
    University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisidero Street, Box 1710, San Francisco, CA 94143 1710, USA
    Breast Cancer Res Treat 137:1-12. 2013
  4. pmc A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
    Hope S Rugo
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143 0875, USA
    Breast Cancer Res Treat 139:411-9. 2013
  5. pmc A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S Rugo
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, B 608, San Francisco, CA 94143, USA
    Breast Cancer Res Treat 134:13-20. 2012
  6. pmc Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis
    Jeffrey K Belkora
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:127. 2009
  7. ncbi request reprint Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials
    Hope Rugo
    University of California, San Francisco, CA 94115, USA
    Clin Breast Cancer 10:288-93. 2010
  8. doi request reprint Cost comparison of capecitabine in patients with breast cancer
    Hope S Rugo
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 94115, USA
    Am J Clin Oncol 33:550-6. 2010
  9. ncbi request reprint Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy
    Hope S Rugo
    Breast Oncology Clinical Trials Program, Comprehensive Cancer Center, University of California San Francisco, 1600 Divisidero Street, San Francisco, CA 94115, USA
    Clin Breast Cancer 7:S21-8. 2007
  10. ncbi request reprint The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
    H S Rugo
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, USA
    Ann Oncol 19:16-27. 2008

Detail Information

Publications47

  1. pmc Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    H S Rugo
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, USA
    Ann Oncol 25:808-15. 2014
    ..We report on the incidence, time course, severity, and resolution of treatment-emergent adverse events (AEs) as well as incidence of dose modifications during the extended follow-up of this study...
  2. pmc Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
    Hope S Rugo
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1710, San Francisco, CA, 94143 1710, USA
    Breast Cancer Res Treat 141:461-70. 2013
    ..Further research is needed to identify potential biologic differences that could have predictive impact for black patients or that could explain these differences. ..
  3. pmc Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
    A Jo Chien
    University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisidero Street, Box 1710, San Francisco, CA 94143 1710, USA
    Breast Cancer Res Treat 137:1-12. 2013
    ....
  4. pmc A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
    Hope S Rugo
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143 0875, USA
    Breast Cancer Res Treat 139:411-9. 2013
    ..In addition, these data suggest that weekly dosing of ixabepilone may be less active than Q3W dosing, but with less neutropenia...
  5. pmc A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S Rugo
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, B 608, San Francisco, CA 94143, USA
    Breast Cancer Res Treat 134:13-20. 2012
    ..Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents...
  6. pmc Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis
    Jeffrey K Belkora
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:127. 2009
    ..We hypothesized that Adjuvant! printouts would be associated with significant changes in the proportion of patients with accurate understanding of local therapy prognosis...
  7. ncbi request reprint Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials
    Hope Rugo
    University of California, San Francisco, CA 94115, USA
    Clin Breast Cancer 10:288-93. 2010
    ..Given the demonstrated improvement in standard outcomes, it is important to assess this therapy's effect on patients' health-related quality of life (HRQOL)...
  8. doi request reprint Cost comparison of capecitabine in patients with breast cancer
    Hope S Rugo
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 94115, USA
    Am J Clin Oncol 33:550-6. 2010
    ..This study compared the cost of capecitabine- and taxane-based regimens in the treatment of breast cancer...
  9. ncbi request reprint Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy
    Hope S Rugo
    Breast Oncology Clinical Trials Program, Comprehensive Cancer Center, University of California San Francisco, 1600 Divisidero Street, San Francisco, CA 94115, USA
    Clin Breast Cancer 7:S21-8. 2007
    ..Data from prophylactic bisphosphonate intervention trials in both post- and premenopausal women will be discussed. Ongoing trials are described...
  10. ncbi request reprint The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
    H S Rugo
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, USA
    Ann Oncol 19:16-27. 2008
    ..Appropriate duration of treatment is another important area of investigation. This review will cover hormonal therapy for postmenopausal women with breast cancer and will not address the treatment of premenopausal women...
  11. doi request reprint The importance of distant metastases in hormone-sensitive breast cancer
    Hope S Rugo
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115 1710, USA
    Breast 17:S3-8. 2008
    ....
  12. doi request reprint Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer
    Hope S Rugo
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Ave, Second Floor, Box 1710, San Francisco, CA 94115, USA
    J Clin Oncol 29:2459-65. 2011
    ..This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC)...
  13. ncbi request reprint The cardiac safety of trastuzumab in the treatment of breast cancer
    A Jo Chien
    University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Expert Opin Drug Saf 9:335-46. 2010
    ..It is critically important to understand the nature of this cardiac risk when counseling patients, especially as new anti-HER2 agents are developed and tested in combination with trastuzumab...
  14. ncbi request reprint Hormonal therapy for advanced breast cancer
    Hope S Rugo
    Breast Oncology Clinical Trials Program, University of California, San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 2nd Floor, San Francisco, CA 94115, USA
    Hematol Oncol Clin North Am 21:273-91. 2007
    ..Current research is focusing on reversing resistance to hormone therapy with the addition of targeted biologic agents to standard hormonal treatment...
  15. pmc Clinical and biomarker predictors of side effects from tamoxifen
    Wendy Lorizio
    Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Breast Cancer Res Treat 132:1107-18. 2012
    ..The association between endoxifen levels and side effects is consistent with the data that suggest that endoxifen is the most highly active metabolite of tamoxifen...
  16. ncbi request reprint Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer
    Sally Greenberg
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
    Clin Breast Cancer 10:S20-9. 2010
    ..Several of these agents have shown considerable promise...
  17. pmc Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer
    Ayca Gucalp
    Authors Affiliations Breast Cancer Medicine Service, Departments of Pathology, Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University, New York Dana Farber Cancer Institute Massachusetts General Hospital, Boston, Massachusetts Mayo Clinic, Rochester, Minnesota Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia University of North Carolina at Chapel Hill, Chapel Hill Duke University Medical Center, Durham, North Carolina University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California University of Alabama at Birmingham, Birmingham, Alabama and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland
    Clin Cancer Res 19:5505-12. 2013
    ..This phase II study explored bicalutamide in AR-positive, estrogen receptor (ER), and progesterone receptor (PgR)-negative metastatic breast cancer...
  18. doi request reprint New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
    Michelle E Melisko
    Breast Oncology Clinical Trials Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115 1710, USA
    Nat Clin Pract Oncol 6:25-33. 2009
    ....
  19. ncbi request reprint Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule
    Lloyd E Damon
    Division of Hematology Oncology, University of California, San Francisco, 400 Parnassus Avenue, Box 0324, San Francisco, CA 94143, USA
    Cancer Chemother Pharmacol 53:468-74. 2004
    ..The differences in toxicity of etoposide following continuous or bolus infusion are unknown...
  20. ncbi request reprint Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Neurooncol 88:359-65. 2008
    ..As breast cancer patients live longer with control of systemic disease, survival after the diagnosis of brain metastases (BM) also appears to be improving...
  21. pmc Amelioration of sexual adverse effects in the early breast cancer patient
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 94115, USA
    J Cancer Surviv 4:247-55. 2010
    ....
  22. ncbi request reprint The role of trastuzumab in early stage breast cancer: current data and treatment recommendations
    Amy Lin
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Curr Treat Options Oncol 8:47-60. 2007
    ..Preliminary data combining trastuzumab with the antiangiogenic antibody bevacizumab is encouraging; this combination will be tested in both early stage and late stage disease...
  23. ncbi request reprint Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical
    Martha Man
    University of California San Francisco Comprehensive Cancer Center, 2nd Floor BCC, 1600 Divisidero Street, San Francisco, CA 94115, USA
    IDrugs 8:739-54. 2005
    ....
  24. ncbi request reprint Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer
    Hope Rugo
    University of California, San Francisco Carol Franc Buck Breast Care Center, San Francisco, USA
    Breast Cancer Res Treat 105:17-28. 2007
    ..We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata...
  25. ncbi request reprint Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors
    Erin Ebbel Niemasik
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, CA 94115, USA
    J Cancer Surviv 6:324-32. 2012
    ..We sought to determine what women recall about reproductive health risks (RHR) from cancer therapy at the time of cancer diagnosis in order to identify barriers to reproductive health counseling (RHC) and fertility preservation (FP)...
  26. doi request reprint The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors
    Meredith Bock
    School of Medicine, University of California, San Francisco, 1106 Stanyan St, San Francisco, CA 94117, USA
    Breast Cancer Res Treat 134:1327-35. 2012
    ..Electronic data collection of BC patient-reported outcomes has a positive effect on symptom management and identification of opportunities for risk-reducing behavior change...
  27. ncbi request reprint Bevacizumab in the treatment of breast cancer: rationale and current data
    Hope S Rugo
    Comprehensive Cancer Center, University of California, San Francisco, 94115, USA
    Oncologist 9:43-9. 2004
    ..The adverse effect profile of bevacizumab differs from that of cytotoxic chemotherapy and includes hypertension, proteinuria, thrombosis, and epistaxis...
  28. doi request reprint Triple-negative breast cancer: role of antiangiogenic agents
    Sally Greenberg
    Department of Medicine, Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
    Cancer J 16:33-8. 2010
    ..Ongoing studies are focusing on the effects of these agents in triple-negative disease, and there is an urgent need to identify markers that can predict response to specific targeted therapy...
  29. ncbi request reprint Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation
    Julie E Lang
    Department of Surgery, University of California San Francisco, San Francisco, CA 94114, USA
    J Am Coll Surg 199:856-62. 2004
    ..It is important to determine whether SSL can be used after neoadjuvant chemotherapy and whether clinical node status at presentation affects accuracy of SSL...
  30. ncbi request reprint Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial
    Suzanne L Dibble
    Institute for Health and Aging, School of Nursing, University of California, San Francisco, USA
    Oncol Nurs Forum 34:813-20. 2007
    ..To compare differences in the chemotherapy-induced nausea and vomiting (CINV) among three groups of women (acupressure, placebo acupressure, and usual care) undergoing chemo-therapy for breast cancer...
  31. ncbi request reprint A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
    Brendan C Bender
    Genentech, Inc, South San Francisco, CA, USA
    Cancer Chemother Pharmacol 70:591-601. 2012
    ..Thrombocytopenia (TCP) is the dose-limiting toxicity of T-DM1. A semimechanistic population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize the effect of T-DM1 on patient platelet counts...
  32. pmc Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery
    Birha McCann
    School of Nursing, University of California, San Francisco, California 94143 0610, USA
    J Pain 13:425-37. 2012
    ..Findings suggest that breast pain occurs in over a quarter of women who are about to undergo breast cancer surgery. Based on phenotypic and genotypic characteristics found, inflammatory mechanisms contribute to preoperative breast pain...
  33. pmc Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
    Wendy Lorizio
    Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero Street, Suite 322, San Francisco, CA 94143 0320, USA
    Genome Med 3:64. 2011
    ..We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study...
  34. ncbi request reprint Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim
    Lloyd Damon
    University of California, San Francisco, San Francisco, California 94143 0324, USA
    Biol Blood Marrow Transplant 12:316-24. 2006
    ....
  35. ncbi request reprint Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers
    Michelle E Melisko
    University of California, San Francisco, USA
    Clin Breast Cancer 6:45-54. 2005
    ..Also, with increasing patient interest in complementary and alternative medicine (CAM) for cancer, we explored attitudes regarding CAM clinical trials...
  36. ncbi request reprint MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival
    Savannah C Partridge
    Department of Radiology, University of California, San Francisco, San Francisco, CA 94143, USA
    AJR Am J Roentgenol 184:1774-81. 2005
    ....
  37. ncbi request reprint Management of breast cancer diagnosed during pregnancy
    Hope S Rugo
    Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Avenue, Second Floor, Box 1710, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 4:165-73. 2003
    ..The physician must have a clear understanding of the pharmacology and teratogenic potential of individual agents, thus limiting risks...
  38. ncbi request reprint High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer
    Uzair B Chaudhary
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Am J Clin Oncol 28:130-7. 2005
    ..A significant correlation was seen between intended carboplatin dose and actual AUC. TVCa high-dose chemotherapy is active and well tolerated in patients with relapsed or refractory germ cell cancer...
  39. doi request reprint Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates
    Jeffrey Belkora
    Department of Surgery, University of California, San Francisco, CA, USA jeff
    Lancet Oncol 9:602-3. 2008
  40. ncbi request reprint Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
    Hope S Rugo
    University of California, San Francisco Comprehensive Cancer Center, USA
    J Clin Oncol 23:5474-83. 2005
    ....
  41. ncbi request reprint Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, IN, USA
    J Clin Oncol 23:792-9. 2005
    ....
  42. doi request reprint Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
    ..This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC)...
  43. ncbi request reprint Bevacizumab for advanced breast cancer
    Tiffany A Traina
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:303-19. 2007
    ..In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer...
  44. ncbi request reprint The role of angiogenesis inhibition in the treatment of breast cancer
    George W Sledge
    Indiana University Cancer Center, Indianapolis, Ind, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Combination therapy consisting of antiangiogenic agents with chemotherapy, hormone therapy, or other agents is also being evaluated in hopes of improving treatment options for these patients...
  45. ncbi request reprint The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research
    Hope S Rugo
    Department of Medicine, University of California Comprehensive Cancer Center, San Francisco 94115, USA
    Semin Oncol 30:749-62. 2003
    ..Herein, the data on cognitive changes associated with chemotherapy for breast cancer, current and future research directions, as well as possible treatments are reviewed...
  46. ncbi request reprint Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy
    Meredith A Wampler
    Department of Rehabilitation, Harrison Medical Center, Bremerton, WA 98310, USA
    Arch Phys Med Rehabil 88:1002-8. 2007
    ..To describe the postural control of women who received taxane chemotherapy for treatment of breast cancer using quantitative and clinically feasible measures...
  47. ncbi request reprint Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    J Clin Oncol 23:5464-73. 2005
    ..Here we present the pharmacodynamic response to acute dosing of AG-013736 measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)...